A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Recent Share Price Pullback

Recent share performance and business scale

Takeda Pharmaceutical (TSE:4502) has drawn investor attention after a recent pullback, with the stock showing a 1.8% decline over the past day and about a 10% decline over the past month.

Over the past 3 months the share price shows about a 5.5% decline, while the 1 year total return stands at 28.2%, the 3 year total return at 32.9%, and the 5 year total return at about 7.4x.

At the last close of ¥5,213, Takeda’s market value stands at about ¥8.2t, supported by annual revenue of ¥4,464,578 and net income of ¥112,926, reflecting its position across gastroenterology, rare diseases, immunology, oncology, and neuroscience.

See our latest analysis for Takeda Pharmaceutical.

The recent 1 month share price return of about 10% decline has cooled short term momentum, while the 1 year total shareholder return above 28% points to a still positive longer term picture.

If Takeda’s move has you rethinking healthcare exposure, it can be useful to see what else is on the radar through a focused set of 8 healthcare AI stocks.

After a strong multiyear total return and a recent pullback, Takeda now trades below analyst price targets and an indicated intrinsic value. This raises a key question for you: is there a genuine buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 14% Undervalued

With the most followed narrative putting fair value around ¥6,036.87 compared with the last close at ¥5,213, the current gap centers on how investors view Takeda’s late stage pipeline and earnings power.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda’s core growth and launch products to drive top-line and earnings recovery going forward. Rapid progress and positive late-stage data from Takeda’s pipeline, especially in high-need therapeutic areas like rare diseases, set the stage for multiple high-value product launches, which can catalyze multi-year revenue and margin expansion.

Read the complete narrative.

Want a clearer picture of why this fair value sits where it does? The narrative focuses on how fast earnings could change relative to modest revenue growth and a richer margin profile, and which profit and valuation assumptions would need to align for that outlook to hold together.

Result: Fair Value of ¥6,036.87 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on avoiding setbacks, such as deeper generic competition around VYVANSE or Entyvio, and any late stage pipeline disappointments that undercut earnings expectations.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Another angle on valuation: earnings multiples

Our model prices Takeda at a fair value of ¥18,813.75 using discounted cash flows, which points to the stock trading at a steep 72.3% discount. Yet the current P/E of 72.9x is very high compared with peers at 18.5x and a fair ratio of 37.5x. Is this a margin of safety or a sign expectations are already stretched?

To see how this P/E gap could close over time, and what that might mean for upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Curious whether the mix of risks and potential rewards here matches your own tolerance and goals? Act while the facts are fresh in mind and pressure test the story against the 2 key rewards and 4 important warning signs

Looking for more investment ideas?

Round out your watchlist with a few more targeted ideas so you are not relying on just one healthcare stock when fresh opportunities are a click away.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com